Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526630 · ClinicalTrials.gov registry record · Phase 4
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
A Phase 4 study of Parkinson's Disease and Gait Impairment, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT00526630: Completed Phase 4 study of Parkinson's Disease and Gait Impairment, sponsored by University of Cincinnati.
NCT00526630 is a Phase 4 study of Parkinson's Disease and Gait Impairment that has completed, run by University of Cincinnati. The registered enrollment target is 23 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00526630, a Phase 4 study of Parkinson's Disease and Gait Impairment, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to examine whether Methylphenidate (MPD) can result in improvement of gait (walking) in a population of Parkinson's Disease (PD) patients whose main disability is freezing of gait. MPD (Ritalin®) is a drug which can excite or stimulate certain systems of the body that control motor function. This drug is FDA approved for the treatment of attention hyperactivity disorder, a condition unrelated to PD. The researchers hypothesize that daily treatment with a tolerable daily oral dose of MPD will improve gait velocity, stride length, cadence, and decrease freezing of gait, 3 months from treatment initiation in patients with moderately advanced PD, whose gait impairment is an important source of disability despite optimized antiparkinsonian treatment.
Primary Outcome
Gait stride length is the distance between two consecutive steps in the "on" state. This will be measured by the GAITRite System, which is an electronic walkway utilized to measure the temporal (timing) and spatial (two dimension geometric position) parameters of its pressure activated sensors.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methylphenidate (MPD)
Study Locations (1)
Ohio
- University Neurology-Movement Disorders Clinic - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
What the finished NCT00526630 record still lists
NCT00526630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00526630 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00526630 about?
NCT00526630 is a clinical study titled "Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease". The purpose of this research study is to examine whether Methylphenidate (MPD) can result in improvement of gait (walking) in a population of Parkinson's Disease (PD) patients whose main disability is freezing of gait. MPD (Ritalin®) is a drug which can excite or stimulate certain systems of the bod...
What is the current status of trial NCT00526630?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2007-12. Estimated completion is 2009-10.
What conditions does trial NCT00526630 study?
This clinical trial studies the following conditions: Parkinson's Disease, Gait Impairment.
What interventions are being tested in trial NCT00526630?
The interventions under investigation include: Placebo (DRUG), Methylphenidate (MPD) (DRUG).
Who is sponsoring clinical trial NCT00526630?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00526630 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00526630's enrollment target sits among peer trials
23 122nd of 158 higher than 35 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
COMPLETED · Phase 4
-
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
COMPLETED · Phase 4
-
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia